ArticleInternational journal of clinical pharmacy2022

Evaluation of osimertinib for advanced non-small cell lung cancer with leptomeningeal metastases: a cost-effectiveness and budget impact analysis.

Shaohong Luo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.